Pharma major Dr Reddy’s Laboratories Ltd has entered into an agreement with Hetero under which Dr Reddy’s has been licensed to distribute and market Sofosbuvir indicated in the treatment of Chronic Hepatitis C.
The drug will be distributed under the brand name Resof in the domestic market.
According to the World health Organization (WHO), close to 12 million Indians suffer from chronic hepatitis C, a disease that can seriously affect the liver, leading to potentially life-threatening complications, including cancer of the liver.
“Clinical studies have indicated that Sofosbuvir in combination with other agents achieved very high cure rates, while shortening the duration of treatment to as little as 12 weeks and reducing or completely eliminating the need for interferon injections, depending on the viral genotype,’’ the company said in a release issued here on Monday.
Dr Reddy’s Co-Chairman & CEO, G V Prasad, commented: ``The launch of Resof is in line with Dr Reddy’s philosophy of innovative medicine at an affordable price and will provide relief to patients.’’